Fluconazole reduced the rate of recurrence of vulvovaginal candidiasis
Q What is the efficacy of fluconazole for recurrent vulvovaginal candidiasis (VC)?
METHODS
Design:
randomised placebo controlled trial.
Allocation:
unclear.
Blinding:
blinded (patients and healthcare providers).
Follow up period:
12 months.
Setting:
multiple centres in the US.
Patients:
387 women ⩾18 years of age (mean age 34 y, 67% white) who had active, acute candida vaginitis (severity score ⩾3), a positive result on microscopic examination of vaginal secretions, ⩾4 episodes of candida vaginitis in the previous 12 months, and were clinically cured (severity score <3) at 14 days after receiving 3 sequential doses of fluconazole, 150 mg, at 72 hour intervals. Exclusion criteria: lack of confirmation of microscopic findings by culture, pregnancy, mixed infections or known seropositivity for HIV, or use of antifungal agents in the previous 4 weeks.
Intervention:
a single oral dose of fluconazole, 150 mg (n = 170),* or an oral placebo tablet taken weekly for 6 months (n = 173).*
Outcomes:
clinical recurrence of …
